enGene is a public clinical-stage biopharmaceutical company based in Montreal, Canada and Boston, United States. enGene is developing a potential best-in-class gene therapies based on its novel DDX delivery platform. The company's lead program, EG-70, is being studied for the treatment of non-muscle invasive bladder cancer (NMIBC). enGene is listed on the NASDAQ under the ticker ENGN.

Specialty

Bladder cancer

Fund name

CTI LSF III

Position

Syndicate

Board

n/a

Investment Date

November 2, 2023

Exit Detail

IPO on the NASDAQ

Initial Series Round

PIPE

Investment Thesis

enGene’s lead program has competitive efficacy and safety data and a distinct delivery advantage, positioning it as the go-to treatment of choice for urologists

Specialty

Fund name

Position

Board

Investment Date

Exit Detail

Initial Series Round

Investment Thesis

Related News

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

enGene, Inc. and Forbion European Acquisition Corp. (“FEAC”, Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies

enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

Phone

Email

Address

Social Media